Patents by Inventor Ernest S. Smith

Ernest S. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Integral membrane protein display on poxvirus extracellular enveloped virions
    Patent number: 11976383
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: May 7, 2024
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maria G. M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
  • METHODS TO SELECT ANTIBODIES SPECIFIC TO COMPLEX MEMBRANE ANTIGENS
    Publication number: 20240093177
    Abstract: This disclosure provides compositions and methods for high throughput screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target integral membrane protein.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 21, 2024
    Inventors: Malgorzata Gil-Moore, Maria G.M Scrivens, Renee A. Kirk, Leslie A. Balch, Loretta L. Mueller, Ernest S. Smith
  • Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
    Patent number: 11534488
    Abstract: Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 27, 2022
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
    Publication number: 20220356249
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 10, 2022
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Human anti-semaphorin 4D antibody
    Patent number: 11427634
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 30, 2022
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Angelica Cornelison, Maria G. M. Scrivens, Mark Paris, Maurice Zauderer
  • ANTI-CD100 ANTIBODIES AND METHODS FOR USING THE SAME
    Publication number: 20220185884
    Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
    Type: Application
    Filed: January 31, 2022
    Publication date: June 16, 2022
    Inventors: Ernest S. Smith, Terrence Lee Fisher
  • Anti-CD100 antibodies and methods for using the same
    Patent number: 11274149
    Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 15, 2022
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Terrence Lee Fisher
  • INTEGRAL MEMBRANE PROTEIN DISPLAY ON POXVIRUS EXTRACELLULAR ENVELOPED VIRIONS
    Publication number: 20210348158
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 11, 2021
    Inventors: Ernest S. Smith, Maria G.M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
  • USE OF SEMAPHORIN-4D INHIBITORY MOLECULES WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASES
    Publication number: 20210324103
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 21, 2021
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
    Patent number: 11078295
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: August 3, 2021
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth Evans, Ernest S. Smith, Maurice Zauderer
  • ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20210087263
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 25, 2021
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
    Publication number: 20210032329
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 4, 2021
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria G.M. SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Integral membrane protein display on poxvirus extracellular enveloped virions
    Patent number: 10870707
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: December 22, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Polynucleotides encoding anti-CXCL13 antibodies
    Patent number: 10829550
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 10, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
    Patent number: 10800853
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 13, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • INTEGRAL MEMBRANE PROTIEN DISPLAY ON POXVIRUS EXTRACELLULAR ENVELOPED VIRIONS
    Publication number: 20200216562
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 9, 2020
    Inventors: Ernest S. Smith, Mark Paris, Maria G.M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
    Patent number: 10662422
    Abstract: The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 26, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Tracy Pandina, Leslie A. Balch, Mark Paris, Maurice Zauderer, Angelica Cornelison, Renee Kirk
  • Integral membrane protein display on poxvirus extracellular enveloped virions
    Patent number: 10577427
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Integral membrane protein display on poxvirus extracellular enveloped virions
    Patent number: 10550199
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: February 4, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases
    Patent number: 10526414
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 7, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer